NEW YORK--(BUSINESS WIRE)--Calibrate, the leading clinician-guided and value-based obesity treatment program, is releasing groundbreaking new results from the largest real-world member cohort yet, with program-wide weight loss surpassing outcomes observed in GLP-1 medication clinical trials. This 2024 Results Report includes data on over 16,000 members and highlights 16.2% average weight loss at 12 months and 17.9% average weight loss at 24 months, coupled with an impressive 78% of members with diabetes or prediabetes reaching normal hemoglobin A1c levels within 12 months.
“The results from our largest-ever data cohort highlight Calibrate’s unique position in addressing the nation's obesity crisis,” said Scott Honken, PharmD, President & Chief Commercial Officer, Calibrate. “Every American living with obesity should have access to effective treatment, and Calibrate is uniquely positioned to provide enterprise companies and payers with a proven best-in-class solution to treat obesity while also helping them navigate the complexities of GLP-1 coverage at a reduced total cost of care.”
Calibrate's industry-leading results outpace clinical trials of popular GLP-1 medications like Wegovy and Ozempic, highlighting the effectiveness of combining GLP-1s with Calibrate’s proprietary ILI (intensive lifestyle intervention).
Key metabolic health outcomes and improvements from patients followed between 12 to 24 months include:
- 16.2% weight loss at 12 months (n=14,255)
- 17.3% weight loss at 18 months (n=4,845)
- 17.9% weight loss at 24 months (n=1,169)
- 6-inch reduction in waist circumference
Kristin Baier, MD, Calibrate’s Vice President of Clinical Development, emphasized the significance of these achievements, "These numbers were achieved amid challenges like nationwide medication shortages and fluctuations in insurance coverage, making them quite remarkable. In addition, we’re extremely proud that 78% of members attained normal A1c levels after starting the program with diabetes or prediabetes. It is also very exciting to see the improvements made among other key metabolic health indicators such as sleep and exercise that go beyond our compelling weight loss and lab value results.”
Some of the other metabolic health indicators highlighted in the Results Report include:
- 58% improvement in food habits
- 49% improvement in exercise
- 38% increase in hours of sleep
- 28% self-reported improvement in emotional health
Calibrate is also the first and only commercial program to present data showing results after members are tapered off GLP-1 medications. Today’s Results Report shows that, among members who discontinued GLP-1, 92% maintained a clinically significant 10% weight loss at least six months post-tapering.
The company is committed to transparency and is the only commercial obesity treatment program to have published real-world data on a member cohort of this size. The most recent report reinforces how the company’s program drives real and sustainable results while reducing healthcare costs and expanding access to care.
The full research abstract can be found here.
About Calibrate
Calibrate is on a mission to change the way the world treats weight. As the leading clinician-guided and value-based outcomes model in obesity treatment, Calibrate combines medication with transformative behavior change to improve overall metabolic health, driving cost-effective, long-term weight loss results while reducing the total cost of care for employers and payers. Recognized by esteemed organizations, including the World Economic Forum’s Technology Pioneers, Fast Company’s World Changing Ideas, TIME’s Best Inventions, and the Employer Health Innovation Roundtable Traction Awards. Calibrate is backed by leading healthcare investors, including Madryn Asset Management, Optum Ventures, and Redesign Health.
